Biopharma returns to MC4R for drugs targeting genetic obesity as well as...
A small but growing cohort of biotech startups — and Pfizer — is focused on developing drugs for one of the most genetically validated pathways in weight control. This includes Superluminal Medicines,...
View ArticleNovo's first obesity deal under new CEO is a $550M pact with RNA startup...
For the second time this summer, Novo Nordisk is teaming up with a biotech startup from the investment firm Apple Tree Partners to create new obesity medicines. Replicate Bioscience will help the...
View ArticleFDA again rejects Outlook Therapeutics’ version of Avastin for wet AMD
The FDA has once again shot down Outlook Therapeutics’ attempt to get its version of bevacizumab approved for wet AMD, stipulating it "cannot approve the application in its present form," the company
View ArticleWhy Twin Health is betting on 'digital twins' to tackle obesity
In the crowded field of treating obesity and diabetes, Twin Health is betting your digital twin is best at helping you lose weight. The California-based startup raised a $53 million Series E, led by...
View ArticleALIGNMT AI raises $6.5M to keep healthcare AI in check
As healthcare ramps up adoption of AI, a new startup is using its own technology to make sure that health organizations’ AI systems remain safe and compliant with regulations. New York-based ALIGNMT AI...
View ArticlePrasad explains why FDA revoked Pfizer's Covid vaccine EUA for children
Following the FDA's more limited approvals of several Covid-19 vaccines on Wednesday, CBER Director Vinay Prasad laid out why the agency decided to rescind Pfizer's emergency use authorization for its...
View ArticleWalgreens names new CEO and splits off businesses as take-private deal closes
Walgreens named Mike Motz as its new CEO. The transition comes as New York-based private equity firm Sycamore Partners closes its $10 billion take-private deal for ...
View ArticleStanford spinout Shenandoah Therapeutics raises $21.5M to turn cancer drivers...
Many cancer drugs work by blocking or destroying a key signal that malignant cells need to stay alive. But researchers at Stanford have devised a way to rewire those signals into one that prompts cell ...
View ArticleProthena reports Phase 1 Alzheimer's data, noting high ARIA-E events
Prothena is putting up a bright, flashing “for sale” sign for an amyloid-targeting Alzheimer’s program. The biotech reported Phase 1 data for four different doses of PRX012 in a Wednesday afternoon
View ArticleREMS tweaks for Travere’s Filspari; AstraZeneca stops early-phase cardio study
Plus, news about Eli Lilly and Cognition Therapeutics: 🔎 FDA simplifies REMS for Travere’s kidney drug: The updated safety strategy for Travere’s Filspari recommends liver monitoring ...
View ArticleGenentech’s $700M North Carolina build; Telix gets CRL for imaging agent
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Roche revealed further information on how it would spend its...
View ArticleHow Scripps Research reinvented its finances to rely less on government grants
A decade ago, 70% of Scripps Research’s funding came from government grants. But that share is now 30%, after Scripps reinvented its financial model to reduce its dependence on Washington. The shift...
View ArticlePersonalizing metabolic care with 'digital twins'
Ngai has a story out today about Twin Health, a startup that raised $53 million in a Series E round this month at a $950 million valuation. The company uses ...
View ArticleFDA takes ‘important step’ toward non-invasive tests for MASH trials
The FDA will look at using a non-invasive test method, rather than liver biopsies, to determine results in some trials of MASH drugs, a measure that could eventually make it easier to enroll patients...
View ArticleBeOne plots accelerated approval for rare lymphoma drug after toplining Phase...
BeOne Medicines said its candidate for a rare but aggressive form of B cell lymphoma has passed an early-stage test. Its BCL2 inhibitor, known as sonrotoclax, met the primary endpoint of overall...
View ArticleAbbVie's Gilgamesh deal highlights pharma's one-asset mind
As the markets have tightened, biopharma companies have gotten creative with their dealmaking structures in recent years. One route — the single-asset deal — has become popular in 2025. Eli Lilly,
View ArticleLongtime Novo Nordisk exec cites 'recent shifts' for his departure; Rocket...
→ Another Lars has left Novo Nordisk. After CEO Lars Fruergaard Jørgensen was replaced by company vet Maziar Mike Doustdar earlier this ...
View ArticleJ&J's immunology hopeful Imaavy fails Phase 2a rheumatoid arthritis study
Johnson & Johnson is expecting its newly-approved Imaavy to be a multibillion-dollar blockbuster across several conditions. But a stumble in a major disease category could hurt those plans. Imaavy...
View ArticleNews briefs: Novocure terminates lung study; FDA approves three-month version...
☑ Zydus Therapeutics’ drug saroglitazar met the primary endpoint in a Phase 2b/3 trial for a rare autoimmune disease that affects the bile ducts, the company announced ...
View ArticlePatient Square raises $3.1B in interim close, as health investor seeks more...
Patient Square Capital, the large healthcare investment firm led by Jim Momtazee, has raised at least $3.1 billion so far for a second fund, according to a securities filing, though the ...
View Article